VTCN1 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VTCN1 status and breast carcinoma as inclusion criteria, 1 is early phase 1 (1 open) [4].

VTCN1 is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VTCN1 status and endometrial carcinoma as inclusion criteria, 1 is early phase 1 (1 open) [4].

VTCN1 is an inclusion criterion in 1 clinical trial for fallopian tube carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VTCN1 status and fallopian tube carcinoma as inclusion criteria, 1 is early phase 1 (1 open) [4].

VTCN1 is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains VTCN1 status and malignant ovarian epithelial tumor as inclusion criteria, 1 is early phase 1 (1 open) [4].

VTCN1 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains VTCN1 status and malignant solid tumor as inclusion criteria, 1 is early phase 1 (1 open) [4].

VTCN1 is an inclusion criterion in 1 clinical trial for primary peritoneal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VTCN1 status and primary peritoneal carcinoma as inclusion criteria, 1 is early phase 1 (1 open) [4].